{"id":"treatment-b","rwe":[{"pmid":"41470102","year":"2025","title":"Effects of Various Local Antibacterial Preparations on Bacterial Density in Pharyngeal and Tonsillar Mucosa of Patients with Acute Pharyngitis.","journal":"Medicina (Kaunas, Lithuania)"},{"pmid":"40896024","year":"2025","title":"The Role of Sesbania grandiflora-Derived Biotin and Bambusa arundinacea-Derived Silica Extracts in Promoting Hair, Skin, and Nail Health: A Randomized, Double-Blind, Placebo-Controlled Clinical Study.","journal":"Cureus"},{"pmid":"40620843","year":"2025","title":"Impact of Albuminuria and Renal Dysfunction on the Anemia-Improving Effect of SGLT2 Inhibitors in Patients With Type 2 Diabetes: A Real-World Observational Study.","journal":"Journal of diabetes research"},{"pmid":"40340713","year":"2025","title":"'More stressful than cancer': treatment experiences lived during Hurricane Maria among breast and colorectal cancer patients in Puerto Rico.","journal":"BMC public health"},{"pmid":"40164501","year":"2025","title":"Reconstitution of CXCR3(+) CCR6(+) Th17.1-Like T Cells in Response to Ofatumumab Therapy in Patients With Multiple Sclerosis.","journal":"Annals of clinical and translational neurology"}],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT00270413","NCT01258088","NCT04919122","NCT06254495","NCT00633386","NCT03351751","NCT01184001","NCT06918002","NCT01243151","NCT03400254","NCT01677065","NCT00982657","NCT00263328","NCT00321308","NCT00407797","NCT01546038","NCT00920478","NCT02767089","NCT01003691","NCT04430738","NCT01208233","NCT00343655","NCT04341181","NCT01297595","NCT03439514"],"aliases":[],"patents":[],"pricing":[],"allNames":"treatment b","offLabel":[],"timeline":[{"date":"2006","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers) — Healthy Adults"},{"date":"2008","type":"negative","milestone":"Phase 2 Initiated","description":"Phase 2 trial (Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer) — Carcinoma, Non-Small Cell Lung. Trial terminated early."},{"date":"2009","type":"negative","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial) — Partial Seizures. Trial terminated early."},{"date":"2022","type":"negative","milestone":"Phase 3 Initiated","description":"Phase 3 trial (A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a La) — Dilated Cardiomyopathy. Trial terminated early."}],"aiSummary":"Treatment B involves the small molecule crenolanib besylate, which is being studied in a Phase II clinical trial for patients with relapsed or refractory acute myeloid leukemia with FLT3 activating mutations. Crenolanib besylate is also being studied for other conditions including chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma, and plasma cell neoplasm.","brandName":"Treatment B","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Single 875 mg dose of mevrometostat alternative tablet formulation","explanation":"","oneSentence":"Single 875 mg dose of mevrometostat alternative tablet formulation","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"treatment-b","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Healthy","phase":"discontinued","trialId":"","patients":null,"diseaseId":"unknown","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00270413","phase":"Phase 2","title":"SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer","status":"Completed","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":19,"indication":"Metastatic Breast Cancer","completionDate":"2009-03","primaryEndpoint":"This study tests the hypothesis that SU11248 can delay tumor progression after tumor mass reduction by taxanes."},{"nctId":"NCT01258088","phase":"Phase 1","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Plaque-type Psoriasis","completionDate":"2010-12","primaryEndpoint":"The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin."},{"nctId":"NCT04919122","phase":"N/A","title":"Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma","status":"Active Not Recruiting","sponsor":"Duke University","isPivotal":false,"enrollment":468,"indication":"Metastatic Renal Cell Carcinoma","completionDate":"2026-12","primaryEndpoint":"ODYSSEY RCC is a prospective, observational Phase IV study is to understand the cancer management and health-related quality of life in patients with mRCC in routine real-world clinical practice in th"},{"nctId":"NCT06254495","phase":"Phase 1","title":"A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers","status":"Active Not Recruiting","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":57,"indication":"Hodgkin Disease","completionDate":"2028-04","primaryEndpoint":"This clinical trial is studying lymphoma."},{"nctId":"NCT00633386","phase":"Phase 4","title":"Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics Af","status":"Completed","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":200,"indication":"Arthroscopy","completionDate":"","primaryEndpoint":"To compare the total analgesic use at 24 hours after arthroscopic knee surgery in patients treated with celecoxib versus placebo."},{"nctId":"NCT03351751","phase":"Phase 1","title":"A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":19,"indication":"Healthy Volunteers","completionDate":"2018-02","primaryEndpoint":"The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects."},{"nctId":"NCT01184001","phase":"Phase 1","title":"A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":16,"indication":"Rheumatoid Arthritis","completionDate":"2010-09","primaryEndpoint":"In this study, a 10 mg tasocitinib (CP-690,550) tablet will be administered to healthy subjects on two separate dosing occasions."},{"nctId":"NCT06918002","phase":"Phase 3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After ","status":"Recruiting","sponsor":"Intergroupe Francophone du Myelome","isPivotal":false,"enrollment":824,"indication":"Multiple Myeloma, Newly Diagnosed","completionDate":"2036-05","primaryEndpoint":"This study is designed as a multicenter, randomized, parallel groups, open-label, phase 3 study in subjects with untreated newly diagnoses Multiple Myeloma eligible for ASCT."},{"nctId":"NCT01243151","phase":"Phase 1","title":"Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolem","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":68,"indication":"Hypercholesterolemia","completionDate":"2011-10","primaryEndpoint":"The primary objective of this study is to evaluate the safety and tolerability of repeated doses of PF-04950615 (RN316) in study volunteers with hypercholesterolemia."},{"nctId":"NCT03400254","phase":"Phase 1/2","title":"Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (\"GLACI","status":"Withdrawn","sponsor":"Abramson Cancer Center at Penn Medicine","isPivotal":false,"enrollment":0,"indication":"Breast Cancer","completionDate":"2019-08","primaryEndpoint":"This clinical trial will assess the safety and early efficacy of the role of gedatolisib and hydroxychloroquine in early-stage breast cancer patients with residual disease and evidence of disseminated"},{"nctId":"NCT01677065","phase":"N/A","title":"A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-rele","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":14,"indication":"Healthy","completionDate":"2012-10","primaryEndpoint":"To determine whether the bioavailability of the controlled-release test formulation is at least as high as that for the commercial reference drug."},{"nctId":"NCT00982657","phase":"Phase 2","title":"A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Adv","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":34,"indication":"Solid Tumor","completionDate":"2014-03","primaryEndpoint":"The safety and tolerability of CVX-060 have been established in the first-in-human clinical trial, CVX-060-101."},{"nctId":"NCT00263328","phase":"Phase 2","title":"Extension Study Of Stage 1 Subjects Of Study A3921009 For The Prevention Of Acute Rejection In Kidne","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":46,"indication":"Kidney Transplantation","completionDate":"2014-01","primaryEndpoint":"A new immunosuppressive drug, based on the inhibition of an important enzyme in the immune system called JAK3, is being developed by Pfizer to prevent transplant rejection."},{"nctId":"NCT00321308","phase":"Phase 2","title":"Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":36,"indication":"Carcinoma, Non-Small Cell Lung","completionDate":"2008-01","primaryEndpoint":"To assess the efficacy and safety of PF-3512676 administered in combination with pemetrexed for the treatment of patients with locally advanced or metastatic NSCLC who have failed one prior chemothera"},{"nctId":"NCT00407797","phase":"Phase 4","title":"Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial","status":"Terminated","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":136,"indication":"Partial Seizures","completionDate":"2009-08","primaryEndpoint":"The purpose of this study is to assess the clinical improvement by partial seizures reduction, safety and tolerability of subjects having partial epilepsy related to the adjunction of pregabalin BID ("},{"nctId":"NCT01546038","phase":"Phase 2","title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelody","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":255,"indication":"Acute Myeloid Leukemia","completionDate":"2017-01","primaryEndpoint":"This is a study to evaluate PF-04449913 (an inhibitor of the Hedgehog pathway) in Acute Myeloid Leukemia and high-risk Myelodysplastic Syndrome in combination with standard agents used to treat these "},{"nctId":"NCT00920478","phase":"Phase 4","title":"Targeting Synovitis in Early Rheumatoid Arthritis","status":"Unknown","sponsor":"NHS Greater Glasgow and Clyde","isPivotal":false,"enrollment":110,"indication":"Rheumatoid Arthritis","completionDate":"2012-09","primaryEndpoint":"Patients with rheumatoid arthritis are at risk of developing permanent joint damage and disability."},{"nctId":"NCT02767089","phase":"Phase 1","title":"The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":37,"indication":"Healthy Adults","completionDate":"2006-03","primaryEndpoint":"The purpose of this study is to further access the utility of biochemical and clinical biomarkers for glucocorticoid-mediated anti-inflammatory effects and safety endpoints against which dissociated a"},{"nctId":"NCT01003691","phase":"Phase 1","title":"Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneratio","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":24,"indication":"Age-Related Maculopathy","completionDate":"2013-03","primaryEndpoint":"The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy."},{"nctId":"NCT04430738","phase":"Phase 2","title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinatio","status":"Active Not Recruiting","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","isPivotal":false,"enrollment":40,"indication":"Colorectal Carcinoma","completionDate":"2024-07","primaryEndpoint":"This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX)."},{"nctId":"NCT01208233","phase":"Phase 2","title":"Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":181,"indication":"Ischemic Stroke","completionDate":"2013-12","primaryEndpoint":"The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke."},{"nctId":"NCT00343655","phase":"Phase 3","title":"Evaluation of Atorvastatin Treatment on Carotid Plaque.","status":"Terminated","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","isPivotal":false,"enrollment":160,"indication":"Cardiovascular Diseases","completionDate":"","primaryEndpoint":"The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necr"},{"nctId":"NCT04341181","phase":"Phase 2","title":"ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profili","status":"Recruiting","sponsor":"Ulrik Lassen","isPivotal":false,"enrollment":300,"indication":"Cancer","completionDate":"2029-04","primaryEndpoint":"The ProTarget study is a phase II, prospective, non-randomized clinical trial with the primary purpose of investigating the safety and efficacy of commercially available cancer drugs that target speci"},{"nctId":"NCT01297595","phase":"Phase 1","title":"Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":22,"indication":"Healthy","completionDate":"2011-04","primaryEndpoint":"This study will be an open-label, randomized, 2-period, 2-treatment, 2-sequence, cross-over single-dose study employing administration of two oral formulations of crizotinib (OLF and FC) in the fasted"},{"nctId":"NCT03439514","phase":"Phase 3","title":"A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a La","status":"Terminated","sponsor":"Pfizer","isPivotal":false,"enrollment":77,"indication":"Dilated Cardiomyopathy","completionDate":"2022-10","primaryEndpoint":"This is a randomized, double-blind, placebo-controlled study in patients with dilated cardiomyopathy (DCM) due to a mutation of the gene encoding the lamin A/C protein (LMNA)."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Other"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":3,"trialStats":{"total":27,"withResults":7},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}